MedPath

Comparisonof the use of Mitomycin C and Triamcinolone in the management of esophageal strictures inchildren which are refractory to standard management

Phase 4
Conditions
Health Condition 1: K23- Disorders of esophagus in diseasesclassified elsewhere
Registration Number
CTRI/2019/01/017262
Lead Sponsor
Rishi Bolia
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All children ( < 13 years ) with refractory or recurrent esophageal strictures , irrespective of the etiology will be included for the trial.

- Refractory strictures will be defined as those in which it is not possible to relieve the

anatomic restriction successfully up to a diameter of 14 mm (12.8 mm. in < 5 years) over

five sessions at 2-3 weekly intervals, due to cicatricial luminal compromise or fibrosis;

- Recurrent strictures will be defined as those in which it is not possible to maintain a

satisfactory luminal diameter for 4 wk once the target diameter of 14 mm (12.8 mm < 5 years ) has been achieved

Exclusion Criteria

- All patients who have received Mitomycin C or triamcinolone in the past.

- Achalasia cardia

- Patients with a history of iatrogenic perforation while undergoing dilataion

- Patients / guardian refusal to give consent / assent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of Triamcinolone vs. Mitomycin â?? C application vs. standard <br/ ><br>management in terms of <br/ ><br>1. Number of sessions of dilatations needed to achieve the target esophageal lumen <br/ ><br>diameter <br/ ><br>2. Number of sessions of dilatations needed for alleviation of dysphagia <br/ ><br>3. Number of patients having a recurrence of symptomsTimepoint: Both triamcinolone or Mitomycin C will be used for a maximum of 4 consecutive sessions. <br/ ><br>After each dilation, patients will remain under observation for at least 4 h. A repeat session <br/ ><br>of dilatation will be performed after 2-3 weeks.
Secondary Outcome Measures
NameTimeMethod
noneTimepoint: N/A
© Copyright 2025. All Rights Reserved by MedPath